| INTRODUCTION
The immunologic environment of the airways plays a critical role in host responses to aeroallergens. Induction of aberrant Th2 responsiveness drives respiratory allergy and asthma in susceptible individuals, 1, 2 whereas protection from allergy is associated with Th1/T regulatory responses. 3, 4 Therapeutic modulation to rebalance Th2-dominated responses may offer clinical benefit for respiratory allergy and potential for disease remission. 5 Toll-like receptors (TLRs) are considered the gatekeepers of the immune system. They recognize potential "danger signals" for the host and trigger immune cascades that elicit the most appropriate type of response to sustain homeostasis and health. 6 Because of this critical role, TLRs have become attractive targets for therapeutic intervention in diseases characterized by dysregulated immunity. 7, 8 In the context of allergy, there is experimental evidence that stimulation of several of the receptors from the TLR family with synthetic ligands produces Th1-type cytokines that attenuate allergen-specific immunoglobulin (Ig) E production and inflammation in target organs, including the airways. 7, 9, 10 Clinical evidence exists for TLR4 or TLR9 agonists as adjuvants of allergen-specific immunotherapy, 11, 12 and for TLR7, TLR8 and TLR9 agonists as standalone allergy drug candidates. [13] [14] [15] Toll-like receptor 7 (natural ligand viral ssRNA) 16 is of particular relevance for respiratory allergies. 17 TLR7 polymorphism has been strongly linked with susceptibility to asthma and other atopic disorders. 18 TLR7 agonists effectively prevent Th2-mediated airway disease in animal models, 9, 10, 19 while they also exhibit a lower proinflammatory profile in comparison with other classes of TLR ligands. 20 This is in part due to the relative restriction of TLR7 expression to plasmacytoid dendritic cells (pDCs) resulting in predominantly type 1 interferon (IFN) responses, rather than pro-inflammatory cytokines such as tumour necrosis factor (TNF)-a and interleukin (IL)-12, which are produced by monocytes and myeloid dendritic cells (MDCs) in response to TLR8 agonists. 21 Furthermore, TLR7-triggered type 1 IFN elicits a protective antiviral immune response. 22 GlaxoSmithKline (GSK) has developed GSK2245035, a highly potent and selective TLR7 agonist. 23 The immunomodulatory potential of GSK2245035 was demonstrated in vitro where it reduced IL-5 and IL-13 and enhanced secretion of IL-10 and IFN-c, in cultures of peripheral blood mononuclear cells from donors with allergic rhinitis (AR). 23 Pharmacological assessment in healthy volunteers and participants with AR indicated that intranasal (i.n.) administration of GSK2245035 results in a dose-dependent activation of TLR7-mediated signalling in the upper airways. 24 Repeat weekly i.n. administration of 40 and 80 ng for 4 weeks was well tolerated and did not result in amplification or tolerization of the pharmacological response. 24 A key challenge with this compound is finding a therapeutic window that allows the induction of the desired local immunomodulatory effects without associated adverse cytokine-mediated events. 25 In this study, we explore the safety and tolerability and pharmacodynamics (PD) of repeat i.n. weekly dosing with GSK2245035 for 8 weeks, specifically the duration of pharmacological changes. Moreover, we examined the effect of treatment on allergic reactivity triggered by nasal allergen Figure 1 ). This follow-up study was performed at the original study site with the same investigator, who remained blinded to the findings and treatment assignment from study TL7116958 (although the sponsor was unblinded to those data).
The randomization schedule was generated by the GSK Clinical for pollen allergens, within a year from the study start; positive screening NAC with the key symptom driving pollen allergen, defined by TNSS response of ≥5 (on a 12-point scale); and decrease in PNIF of >30%. Owing to low participant recruitment, and given that the primary end-point related to safety, a protocol amendment in January 2014 removed the requirement for mild asthma; a methacholine provocation test (described in Appendix S1) was then conducted only if the participant had a history of asthma. Exclusion criteria are listed in the Appendix S1. In the 2014 Cohort, participants received GSK2245035 at a concentration of 10 ng/actuation (total dose of 20 ng).
| Treatments
2.4 | End-points and assessments
| Primary end-points
Primary end-points comprised general safety end-points, nasal tolerability end-points and TLR7-induced serum and nasal PD biomarkers.
Safety end-points
The primary safety end-points included AEs and CytoRS-AEs. CytoRSAEs (headache, fever, chills/rigour, nausea, arthralgia, myalgia, vomiting, diarrhoea, hypotension) occurring within 24 hours post-dose were graded 0-4 according to severity, based on the National Cancer Institute Common Toxicity Criteria guidelines. 27 Also assessed were vital signs, clinical laboratory parameters and peak expiratory flow.
Nasal tolerability end-points
Nasal tolerability was assessed via nasal examination and participants' scoring on a 10-cm visual analogue scale (VAS) at 10 hours and 24 hours post-dose to assess itching, discomfort, post-nasal drip, rhinorrhoea and obstruction (ranging from "no symptoms" to "worst symptoms ever experienced").
TLR7-induced serum and nasal PD biomarkers
The primary PD end-points included levels of the TLR7-induced biomarkers used in the previously reported study 24 
| Exploratory end-points
Exploratory end-points included efficacy as determined by reduction in nasal symptoms following allergen challenge and allergic reactivity biomarkers.
Nasal allergen challenge (NAC) was performed at screening, to confirm eligibility, prior to randomization to provide baseline data, 
Nasal symptoms
Nasal symptoms (congestion, rhinorrhoea, sneezing, itch) elicited by NAC at screening, FUV1, FUV2 and FUV3 were assessed individually and as a TNSS. TNSS and PNIF were assessed prior to the allergen challenge and at 15 (primary NAC comparison time-point) and 30 minutes and 1, 2, 3, 4, 5 and 6 hours after the end of the challenge. TNSS was derived from symptom scores graded as: 0=none: no symptom whatsoever, absent; 1=mild: symptom is present, noticeable but not bothersome; 2=moderate: symptom is bothersome, but tolerable; and 3=severe: symptom is bothersome, hard to tolerate, requiring relief/ treatment with a maximum score of 12. PNIF was determined using the In-Check TM PNIF meter (Alliance Tech Medical Inc. TX, USA). 
Allergic reactivity biomarkers

| Statistical analysis
No formal statistical hypotheses were planned to be tested and no formal sample size estimated. Following the protocol amendment, the anticipated sample size of 14 participants receiving active treatment was considered sufficient for the safety and PD profile of GSK2245035 supporting larger clinical trials. NAC and biomarker analyses were performed on the per-protocol population, which was defined post hoc and excluded three participants receiving incorrect levels of allergen at a FUV. Year-matched placebo data were used for comparisons of TNSS, body temperature, serum and nasal lavage biomarker levels (excluding analyses exploring TLR-7 target engagement during the dosing period; post hoc); placebo cohorts were pooled as planned for all other end-points. Point estimates and corresponding 95% credible intervals (CrI) were obtained for selected assessments to determine the induction of TLR7-associated serum and nasal PD biomarkers. A Bayesian approach was employed to investigate mean effect sizes of exploratory end-point findings. For reference, a significant P-value from a two-sided test at the 5% level is equivalent to the posterior probability (PP) exceeding 0.975. PP>0.9 is generally defined as high certainty of the observed value representing a true treatment effect. Further details on the statistical analyses are presented in Appendix S1. (Table S1 ). No serious AEs or deaths were reported.
Only two AEs were reported during the follow-up study; both occurred in the same participant in the placebo group and were not considered related to study treatment.
| CytoRS-AEs
CytoRS-AEs within 24 hours of dosing were observed in 93% (13/ 14) of participants in the 80 ng group and less frequently in the 20 ng (36%; 5/14) and placebo (29%; 4/14) groups (Table 2) .
Headache was the most frequent CytoRS-AE in all treatments followed by fever, observed only in the 80 ng group. Apart from one participant in the placebo group who experienced severe headache, severe-grade CytoRS-AEs were only observed in the 80 ng group (36%), where one participant was withdrawn owing to severe myalgia.
In the 80 ng group, headache and fever were reproducible CytoRSAEs; two participants reported a CytoRS-related headache with each dose, one of whom also had CytoRS-related fever with seven doses (Figure 3 ). In contrast, of the five participants in the 20 ng group who reported a CytoRS-AE, three reported it at only one visit. The median duration of CytoRS-AEs induced by both doses was <24 hours, with the exception of chills/rigours in the 20 ng group (n=2; mean 26 hours).
| Vital signs, clinical chemistry and haematology
In the majority of participants in all groups, vital signs were normal for the duration of the study. Further details are provided in the Appendix S1. Decreases in peripheral blood lymphocyte numbers were observed at 24 hours after DV1 and DV8 in the 20 ng group and at 8 hours and 24 hours after DV1 and DV8 in the 80 ng group, with greater than 95% certainty ( Figure S1 ). (Figure 4) . The mean body temperature increase after each dosing in both dose groups was less than 1°C, except in the 80 ng group after DV2. BMI, body mass index; NAC, nasal allergen challenge; SD, standard deviation; GSK, GlaxoSmithKline.
| Nasal tolerability
; T A B L E 1 Participant demographics and baseline
T A B L E 2 Summary of CytoRS-AEs (occurring within 24 h postdose)
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Placebo N=14 and DV8 only shown in Figure S2 ).
Additional safety assessments including peak expiratory flow measurements, nasal examinations (Table S2 ) and nasal symptoms as recorded on daily diary cards did not reveal adverse effects with repeat dosing.
3.3 | TLR7-induced serum and nasal PD biomarkers
| Serum IP-10
Median fold changes in serum IP-10 levels increased with certainty (PP>0.98) at 24 hours after DV1 and DV8 for both doses versus placebo ( Table 3 ). The fold changes compared with placebo (95% CrI)
were greatest in the 80 ng group at both DV1 and DV8. In the 80 ng group, an increase in serum IP-10 level was observed at FUV1 (PP>0.99; Table 3 ).
| Nasal IP-10
Median fold changes in nasal lavage IP-10 levels increased with certainty (PP=1.0) at 24 hours after DV1 and DV8 for both doses, versus placebo (Table 3 ). For the 20 ng group, the magnitude of fold change versus placebo (95% CrI) at 24 hours post-DV8 was higher than post-DV1. Median fold changes in the 80 ng group remained similar at 24 hours after DV1 and DV8. In the 80 ng group, an increase in nasal IP-10 levels was observed at FUV1 and at FUV2 (PP>0.96; Table 3 ).
| TNF-a, IL-6 and IFN-a
Serum levels of TNF-a were not detectable in any group (lower limit of quantification [LLQ] 9.38 pg/mL). Serum levels of IFN-a were detectable (LLQ 12.5 pg/mL) at one or more study visits in two participants in the placebo group, eight in the 20 ng group and two in the 80 ng group.
Median fold changes of TNF-a and IL-6 in nasal lavage samples (Table S3 ). The median change from baseline in TNSS showed no reduction with GSK2245035 20 ng compared with placebo at FUV3 ( Figure 5 and Table S3 ).
| PNIF
No consistent changes were noted in PNIF post-NAC at FUV1, FUV2 or FUV3 for any treatment group (data not shown). (Table S4) . Range within which the true value lies with 95% probability (certainty). hindsight appears less reliable than in protocols where a 50% reduction is required. 33 While no standardized minimum clinically important difference has been established for TNSS, these results are of a similar or greater magnitude to i.n. corticosteroid studies where the effects are present over a 24-hour dosing period. [34] [35] [36] [37] [38] Here, the probability of a sustained treatment effect on TNSS for both doses was modest to high, about 90%, at 1 week and 84% at 3 weeks after treatment. | 1201
| Allergic reactivity biomarkers
GSK2245035 despite the small sample size used in this study. The
Bayesian statistical methods allow judgement on the strength of the data by providing a probability that the observed treatment effect is not chance. In this study, the probabilities of mean changes in IP-10 levels exceeded 0.975 and were equivalent to a P-value <.05. When applied to exploratory efficacy end-points, Bayesian methods show the probability of each GSK2245035 dose inducing a reduction in nasal symptoms to be high at FUV1 and FUV2, not at the level generally associated with "proof" for definitive efficacy studies, rather as an informative way of assessing data in translational medicine studies such as this. Similarly, the probabilities of reducing individual Th2 cytokines or chemokines were moderate to high. These findings were demonstrated in a relatively small number of participants and would need to be confirmed in larger studies. GSK2245035 is yet to be determined, and Th1/regulatory responses were not detected, the i.n. reductions in IL-5, Th2 chemokines and ECP provide evidence for a treatment effect on Th2-associated inflammation.
Perhaps the greater challenge will be to link these changes in immune responses to the clinical benefits perceived by the patient.
By altering established immune responses to aeroallergens, TLR7 agonism has broad therapeutic utility. I.n. GSK2245035 is conveniently administered once weekly and the relevant therapeutic comparison will be to a daily i.n. corticosteroid. As an immunomodulatory treatment that works with natural allergen exposure, a key advantage might be the low risk of anaphylaxis, and its safe use also in season. Lastly, although the serum allergic biomarkers did not reveal systemic treatment-related effects, the PD data (ie raised serum IP-10 and body temperature, and decreased blood lymphocyte counts) suggest that an effect of i.n. GSK2245035, via the induced type 1 IFN response, may not be restricted to the local nasal environment. Therefore, TLR7 remains a valid target with the prolonged local clinical effects and self-resolving AEs providing evidence for a therapeutic window.
